Weight Loss, Muscle Mass, Heart Risk: Major Study Decodes Strengths and Weaknesses of 19 GLP-1 Drugs

A large comparative study evaluating 19 GLP-1-based therapies has provided one of the clearest pictures yet of how popular weight-loss and diabetes medications stack up against one another, highlighting differences in their effectiveness for weight reduction, muscle mass preservation, heart health and safety.

The research analysed data from multiple clinical trials involving GLP-1 receptor agonists and combination therapies that are increasingly prescribed to treat obesity and type 2 diabetes. While most drugs in the class demonstrated significant benefits, the study found that no single medication excelled across every health outcome.

Weight loss benefits vary across treatments

According to the analysis, newer-generation GLP-1 and dual-action therapies generally delivered the greatest reductions in body weight, outperforming earlier medications in the class. Researchers noted that these drugs not only helped patients lose weight but also improved blood sugar control and several metabolic health markers.

Experts say the findings reinforce the growing role of GLP-1 medicines in obesity management, particularly for patients whose lifestyle modifications alone have not produced sufficient results.

Muscle loss remains a key concern

One of the study's notable findings relates to lean muscle mass. While weight loss is a primary goal of treatment, researchers cautioned that some patients may also lose muscle alongside body fat.

The study stressed the importance of combining GLP-1 therapy with adequate protein intake and resistance exercise to help preserve muscle during weight reduction. Physicians may also need to monitor body composition rather than relying solely on changes in body weight.

Cardiovascular protection differs between drugs

Researchers also compared the cardiovascular effects of the medications, including their impact on heart attack, stroke and cardiovascular-related deaths.

Several GLP-1 therapies demonstrated substantial cardiovascular benefits, particularly among people with type 2 diabetes and those at high risk of heart disease. However, the magnitude of protection varied between drugs, suggesting treatment choices may depend on a patient's individual cardiovascular profile in addition to weight-loss goals.

Side effects remain largely gastrointestinal

The analysis found that nausea, vomiting, diarrhoea and constipation remained the most common side effects across the drug class. Most adverse effects were mild to moderate and tended to improve as treatment continued or doses were gradually increased.

Researchers emphasised that healthcare providers should weigh the benefits against potential side effects when selecting the most appropriate medication for individual patients.

Personalised treatment is key

The authors concluded that treatment decisions should not be based solely on the amount of weight loss a drug produces. Factors such as cardiovascular disease, diabetes, kidney function, age, muscle preservation and tolerance to side effects should all influence prescribing decisions.

Medical experts say the findings reflect the broader shift toward personalised obesity care, where therapy is tailored to a patient's overall health profile rather than focusing on a single outcome.

With GLP-1 medications continuing to reshape the treatment landscape for obesity and diabetes, the study offers valuable evidence to guide clinicians and patients as they navigate an expanding range of therapeutic options.